6504 Survial advantage for irinotecan versus best supportive care (BSC) as 2nd-line chemotherapy in gastric cancer – a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)P. Thuss-Patience, Peter Reichardt, Dmitry Bichev et al.|European Journal of Cancer Supplements|2009Cited by 9
Recurrent Gastric Adenocarcinoma with Unusual Metastatic Localization and Excellent Responseto Docetaxel and 5-FU Continuous InfusionP. Thuss-Patience, Peter Reichardt, Albrecht Kretzschmar et al.|Oncology Research and Treatment|2003Cited by 3
Hepatic artery infusion (HAI) of oxaliplatin (Ox) as third and fourth-line therapy for patients with hepatic metastases (M) from colorectal cancer (CRC) pretreated with systemic OxHella Gollasch, Albrecht Kretzschmar, Bernhard Gebauer et al.|Journal of Clinical Oncology|2004Cited by 3
Docetaxel and 5-FU continuous infusion (DF) versus epirubicin, cisplatin and 5-FU (ECF) for advanced gastric adenocarcinoma; a randomized phase II studyP. Thuss-Patience, Peter Reichardt, Albrecht Kretzschmar et al.|European Journal of Cancer|2001Cited by 2
3558 POSTER Metastatic small bowel adenocarcinoma: favourable outcome in patients with primary tumour resected – retrospective analysis of 44 casesAlbrecht Kretzschmar, Jakob Hartmann, Daniel Pink et al.|European Journal of Cancer Supplements|2007Cited by 0